Clinical News

Fourth report of the biological therapy element of the UK IBD audit

Thursday, 24 September 2015 14:32

Latest UK IBD audit report shows further improvement for patients following treatment with biological therapies

The UK inflammatory bowel disease (IBD) clinical audit report reveals today that the majority of patients (80% adult and 77% paediatric) with Crohn's disease saw an improvement following biological therapies

This is the fourth report of the biological therapy element of the UK IBD audit. The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.

The data presented in the reports demonstrate that biological therapies for IBD are effective and relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar with these drugs.

National and executive summary versions of both adult and paediatric reports are available on the Royal College of Physicians' website:

NICE guidance on the use of vedolizumab in Crohn's disease

Wednesday, 26 August 2015 08:53

Single Technology Appraisal (STA) - Vedolizumab for the treatment of adult patients with moderately to severely active Crohn's disease [ID690]

The Final Guidance will be published on the NICE website: http://www.nice.org.uk/guidance/indevelopment/gid-tag461 on 26th August 2015. There will also be a version of the guidance available for people using services, carers and the public called 'Information for the public'. Additionally, the documentation used to develop the guidance such as the underpinning evidence submissions, will remain on the website.

A copy of the guidance is available for you to download from NICE Docs: https://appraisals.nice.org.uk/request/7289

"The BSG welcomes the publication of this guidance on the use of Vedolizumab in Crohn's disease. A significant number of patients suffering from Crohn's disease fail to benefit from anti-TNF therapy, and for them the availability of a drug therapy that has a completely different mode of action, with good trial evidence of efficacy and safety is most welcome."

Dr AB Hawthorne,
IBD section chairman

Independent Cancer Taskforce Report

Monday, 27 July 2015 11:27

The Independent Cancer Taskforce has published its report, Achieving world-class cancer outcomes: a strategy for England 2015-2020. This report sets out recommendations for a new cancer strategy for England. An Executive Summary and press release are also available.

The Chair of the Taskforce, Harpal Kumar, sets out the opportunities to transform cancer services in a letter to the Chief Executives of the bodies responsible for running the NHS, and on the Cancer Research UK blog.

New Study Highlights Urgent Need to Improve GI Bleed Service Coverage

Friday, 03 July 2015 11:33

The British Society of Gastroenterology (BSG) has welcomed the publication of a landmark report into gastrointestinal (GI) bleed services, and repeated its calls for urgent action to improve service provision and protect safety for all patients in the UK.

Half of hospitals that patients are admitted to as an emergency cannot provide all the services they might need for a GI bleed, according to the study by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD). In addition, NCEPOD found that 32% of hospitals in their sample admitting GI bleed patients did not have a 24/7 endoscopy service, and issued a clear call for this to change.

The BSG has been working with its members and relevant agencies for several years to improve the provision of acute upper GI bleed (AUGIB) services, including through:

  • A series of clinical audits on GI Bleeds nationally, including the audit conducted with the National Blood Service reported in 2010
  • Working with NHS Improving Quality (NHS IQ) to audit services across England, documented in the launch of a report in 2014 which included models for service improvement
  • Developing an Upper GI Toolkit with the Academy of Medical Royal Colleges
  • Contributing to the development of NICE guidance
  • Holding workshops with NHS IQ for BSG members on how services could be improved
  • Held a number of events at its annual conferences to highlight the issue

In addition to this, work is ongoing with NHS England to re-audit services to see where improvements have been made over the past two years. The BSG membership is united in its determination to see service change to make sure that patients with a GI bleed have access to the specialist services they need in an appropriate and timely manner.

Commenting, British Society of Gastroenterology President, Dr Ian Forgacs, said:

"This report is another important reminder of the urgent need to ensure that patients everywhere have access to GI bleed services available 24/7 either onsite or through a comprehensive network.

"Working with members to improve these services has been a key priority both for myself and the BSG for many years now, and this report is a reminder that there is still some way to go to deliver the services patients need and deserve.

"With the current political focus on delivering seven day services, particularly in areas where there is a high risk of mortality without appropriate treatment, there is a strong case for improving GI bleed services to be a key part of that agenda and we hope this report will help to build momentum and will for change around this issue.

"Until we see wholesale change to safe, comprehensive and high quality service coverage, the improvement of GI bleed services will remain a top priority for the BSG and its members."

Page 14 of 16